Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
Product
TLANDO®
TLANDO® Product Site
TLANDO®
TLANDO® Product Site
Technology
Li’pral Technology
Li’pral Technology
Investors/Media
Press Releases
Presentations/Events
SEC Filings
Investor FAQ
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Press Releases
Press Releases
October 10, 2024
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Read More
October 8, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Read More
October 2, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Read More
August 27, 2024
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Read More
August 8, 2024
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
Read More
August 6, 2024
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Read More
June 25, 2024
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Read More
June 10, 2024
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Read More
May 9, 2024
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Read More
Focus on enhancing health
We are pioneers of developing innovative drug products targeting significant unmet medical needs.